Peptide Registry

Vials

Capsules

Liquids

a vial of Selank/Semax 10/10mg

Selank/Semax

$59.00

  • Contents: Selank/Semax Blend (equal-ratio heptapeptide combination)
  • Form: Lyophilized powder
  • Purity: >99%
Quantity Discount Price
1 - 3 - $59.00
4 - 7 10% $53.10
8 + 18% $48.38
SKU: N/A Category: Brand:

Description

The Selank/Semax Blend combines two structurally unrelated heptapeptides from Russian neuropharmacological research programs in an equal-ratio formulation. Semax is derived from the ACTH(4-10) fragment and operates through the neurotrophic axis: melanocortin receptor interaction drives BDNF and NGF upregulation, TrkB receptor pathway activation, and modulation of dopaminergic and serotonergic neurotransmitter systems. Selank is a tuftsin-derived analog that operates through the GABAergic inhibitory axis: positive allosteric modulation of GABA-A receptor-mediated signaling, serotonergic modulation, and enkephalin degradation inhibition through enzyme activity effects. These two mechanistic axes do not overlap at the receptor level, making the combination a tool for nootropic peptide research models where simultaneous neurotrophic activation and GABAergic inhibitory signaling are the experimental conditions.

Chemical Information

Semax Component:

  • Chemical Name: Semax (Met-Glu-His-Phe-Pro-Gly-Pro; ACTH 4-10 fragment)
  • Compound Class: Synthetic ACTH-derived heptapeptide; melanocortin pathway modulator
  • Molecular Weight: approximately 887 Da
  • Primary Axis: Neurotrophic (BDNF/NGF upregulation; TrkB pathway)

Selank Component:

  • Chemical Name: Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; tuftsin heptapeptide analog)
  • Compound Class: Synthetic tuftsin-derived heptapeptide; GABAergic inhibitory modulator
  • Molecular Weight: approximately 863 Da
  • Primary Axis: GABAergic inhibitory (GABA-A positive allosteric modulation; enkephalinergic)

Blend:

  • Ratio: Selank 10mg / Semax 10mg (equal weight)
  • Shared structural feature: C-terminal Pro-Gly-Pro extension (both compounds; improves metabolic stability)
  • Production: Solid-phase peptide synthesis (SPPS) for both components

Applications

  • Dual-pathway CNS neurotransmitter research. The blend simultaneously activates the BDNF/TrkB neurotrophic axis (Semax) and the GABAergic inhibitory axis (Selank) in the same experimental model; the two receptor systems operate independently with no direct mechanistic overlap, making this a tool for studying how simultaneous neurotrophic and inhibitory signaling inputs interact in CNS cell models
  • BDNF upregulation and GABAergic tone comparative research. Semax drives BDNF gene expression through melanocortin receptor interaction while Selank modulates GABA-A receptor-mediated inhibitory tone; studying both simultaneously enables examination of how neurotrophic factor availability and inhibitory circuit modulation interact in hippocampal and cortical cell populations
  • Enkephalinergic and dopaminergic co-modulation research. Selank inhibits enzymes that degrade enkephalins while Semax modulates dopaminergic neurotransmission; the blend enables study of endogenous opioid and monoamine pathway co-modulation in the same neuronal model
  • Single-compound versus combination comparative designs. Semax and Selank are available as standalone research compounds; the blend format enables direct experimental comparison of dual-pathway combined conditions against single-pathway controls, which is the primary research value of the blend format for attributing observed effects
  • Neuroimmune and neurotrophic signaling intersection. Selank retains tuftsin’s neuroimmune regulatory properties alongside its GABAergic effects; Semax drives neurotrophic factor upregulation; the intersection of immune and neurotrophic signaling in CNS tissue models is a research question the blend enables within a single experimental condition

Storage and Handling

Store lyophilized blend at -20C for long-term stability, or at 2-8C for short-term use. Protect from heat, moisture, and direct light. Both components share comparable stability profiles as lyophilized heptapeptides with Pro-Gly-Pro C-terminal extensions. Reconstitute immediately before use and avoid repeated freeze-thaw cycles to preserve the integrity of both components.

Compliance Notice

Selank/Semax Blend is for laboratory research use only. They are not for human or veterinary use and carry no therapeutic, diagnostic, or clinical indication. FDA has not evaluated this product. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.

Frequently Asked Questions

What is the mechanistic rationale for combining Semax and Selank in research?

Semax operates through the neurotrophic axis: ACTH-derived melanocortin receptor interaction drives BDNF and NGF upregulation and TrkB pathway activation. Selank operates through the GABAergic inhibitory axis: tuftsin-derived positive allosteric modulation of GABA-A receptor-mediated signaling alongside enkephalin degradation inhibition. These two mechanistic axes do not share receptor targets, making their simultaneous activation a genuinely independent dual-pathway experimental condition rather than redundant stimulation of the same system. Researchers use the combination to study how neurotrophic factor availability and inhibitory circuit modulation interact when both are simultaneously active in the same neuronal model.

Is there published research specifically on the Semax and Selank combination?

No formal published clinical or preclinical study has evaluated the specific Semax and Selank combination as a formulated blend. The combination rationale is mechanistic, derived from each compound's individual published literature and the observation that their receptor targets and downstream pathways do not overlap. Researchers using this blend should include single-compound control arms for Semax alone and Selank alone alongside the combination condition. Without these controls, observed effects cannot be attributed to either component or to their interaction.

How does the Selank/Semax Blend differ from the N-Acetyl modified analogs?

Semax and Selank both have N-terminal acetylation and C-terminal amidation variants (N-Acetyl Semax Amidate and N-Acetyl Selank Amidate) that improve proteolytic stability at both termini. The unmodified forms in this blend carry the native sequences with the Pro-Gly-Pro C-terminal extension providing stability at the C-terminus. Researchers selecting between the standard and modified forms should consider whether the experimental protocol requires the native published sequences for direct comparison with existing literature, or whether improved stability from dual terminal modification is required for longer-duration protocols. The mechanistic research context is the same across both forms; the pharmacokinetic profile is not.

Related products